Humoral and cellular responses after third dose of SARS-CoV-2 vaccine in myeloproliferative neoplasms patients on ruxolitinib therapy Published on 2023-05-292024-09-05 Journal: Leukemia research [키워드] COVID19 MPN myeloproliferative neoplasms Ruxolitnib SARS-CoV-2 Vaccine [저자] A. Atanasio, A. Vanni, L. Maggi, S. Pilerci, A. Mazzoni, M. Capone, F. Crupi, P. Cicogna, V. Boldrini, S. Tekle, M.G. Colao, M. Borella, C. Paoli, G.M. Rossolini, A.M. Vannucchi, F. Annunziato, P. Guglielmelli [Category] update2024, PMC URL Pubmed URL DOI URL [DOI] 10.1016/j.leukres.2023.107330 [Article Type] Letter to Editor [Source] PMC All Keywords 【저자키워드】 SARS-CoV-2, Vaccine, COVID19, myeloproliferative neoplasms, MPN, Ruxolitnib,